ZIGNEGO, ANNA LINDA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 23.217
EU - Europa 14.933
AS - Asia 3.022
AF - Africa 191
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 8
SA - Sud America 5
Totale 41.385
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 23.151
RU - Federazione Russa 5.240
PL - Polonia 3.041
IE - Irlanda 1.845
SE - Svezia 1.424
IT - Italia 1.264
SG - Singapore 927
HK - Hong Kong 745
UA - Ucraina 705
CN - Cina 500
FI - Finlandia 498
DE - Germania 481
IN - India 320
TR - Turchia 301
GB - Regno Unito 212
CI - Costa d'Avorio 164
VN - Vietnam 145
CA - Canada 59
FR - Francia 58
JO - Giordania 52
BE - Belgio 41
ES - Italia 37
CH - Svizzera 29
NL - Olanda 27
SC - Seychelles 18
CZ - Repubblica Ceca 15
KR - Corea 15
AU - Australia 8
EU - Europa 8
JP - Giappone 7
MX - Messico 7
EG - Egitto 6
BG - Bulgaria 5
BR - Brasile 4
IL - Israele 4
PK - Pakistan 4
AT - Austria 2
BF - Burkina Faso 2
LT - Lituania 2
NO - Norvegia 2
RO - Romania 2
DK - Danimarca 1
ID - Indonesia 1
IR - Iran 1
KE - Kenya 1
MD - Moldavia 1
NZ - Nuova Zelanda 1
SK - Slovacchia (Repubblica Slovacca) 1
UY - Uruguay 1
Totale 41.385
Salva come PNG Salva come JPEG
Città #
Santa Clara 3.386
Warsaw 3.036
Fairfield 2.633
Dublin 1.843
Chandler 1.762
Ashburn 1.230
Woodbridge 1.162
Cambridge 1.092
Seattle 1.053
Jacksonville 1.012
Wilmington 956
Houston 922
Singapore 711
Princeton 565
Altamura 480
Ann Arbor 463
Lawrence 436
Boston 362
Boardman 311
Mumbai 305
Hong Kong 292
Medford 269
Buffalo 266
Izmir 258
Florence 250
Beijing 241
Abidjan 164
San Diego 145
Norwalk 144
Dong Ket 118
Shanghai 115
Falls Church 113
Moscow 92
Bremen 80
Hillsboro 67
Andover 55
Dearborn 53
Milan 50
Toronto 46
Brussels 39
New York 39
Frankfurt Am Main 32
Washington 32
Salerno 31
Los Angeles 30
Redmond 30
West Jordan 30
Bern 29
Yubileyny 29
Auburn Hills 28
Rome 25
Verona 25
Barcelona 23
Munich 22
Laurel 21
Saint Petersburg 21
London 19
Phoenix 18
Old Bridge 17
Kent 16
Brno 15
Pamplona 12
Nanjing 11
Tappahannock 11
Helsinki 9
Padova 9
Seoul 9
Guangzhou 8
Kunming 8
Frankfurt am Main 7
Castelliri 6
Catania 6
Montréal 6
Bagno a Ripoli 5
Grafing 5
Grevenbroich 5
Guadalajara 5
Paris 5
Philadelphia 5
San Mateo 5
Sofia 5
Aachen 4
Avigliano 4
Bologna 4
Brescia 4
Caserta 4
Genoa 4
Kilburn 4
Messina 4
Naaldwijk 4
Pune 4
Redwood City 4
Taranto 4
Amsterdam 3
Azor 3
Bari 3
Brooklyn 3
Cagliari 3
Casalecchio di Reno 3
Central 3
Totale 27.320
Salva come PNG Salva come JPEG
Nome #
Serum hepatitis delta virus RNA in patients with delta hepatitis and in liver graft recipients 1.128
Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis 264
Role of MicroRNA Profile Modifications in Hepatitis C Virus-Related Mixed Cryoglobulinemia 247
Hepatitis C Virus infection in the immunocompromised host: a complex scenario with variable clinical impact 242
Evaluation of the prognostic value of liver stiffness in patients with hepatitis C virus treated with triple or dual antiviral therapy: A prospective pilot study 240
Individualized treatment of genotype 1 naïve patients: an Italian multicenter field practice experience. 227
Assessment of liver stiffness in patients with HCV and mixed cryoglobulinemia undergoing rituximab treatment. 224
HCV and lymphoproliferation 221
Liver cancer-derived hepatitis C virus core proteins shift TGF-beta responses from tumor suppression to epithelial-mesenchymal transition 219
Identification of new autoantigens by protein array indicates a role for IL4 neutralization in Autoimmune Hepatitis 218
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network 212
Impact of immunogenetic IL28B polymorphism on natural outcome of HCV infection. 210
Hepatitis C virus infection and arthritis. A clinico-serological investigation of arthritis in patients with or without cryoglobulinemic syndrome 204
Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study 200
Mixed cryoglobulinemia, lymphomas and HCV 198
Genetic diversity of the KIR/HLA system and susceptibility to hepatitis C virus-related diseases 188
Notch4 and mhc class II polymorphisms are associated with hcv-related benign and malignant lymphoproliferative diseases 180
Strategie terapeutiche nella crioglobulinemia mista: recenti acquisizioni 178
International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement 161
HCV-related liver and lymphoproliferative diseases: Association with polymorphisms of IL28B and TLR2 154
The metabolic fingerprints of HCV and HBV infections studied by Nuclear Magnetic Resonance Spectroscopy 154
Assessment of free light chains in HCV-positive patients with mixed cryoglobulinaemia vasculitis undergoing rituximab treatment 154
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 151
Combined treatment with antiviral therapy and rituximab in patients with mixed cryoglobulinemia: review of the literature and report of a case using direct antiviral agents-based antihepatitis C virus therapy 151
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 151
Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: Phase II clinical trial and systematic review 150
Interferon-free therapy in hepatitis C virus mixed cryoglobulinaemia: a prospective, controlled, clinical and quality of life analysis 149
MR-diffusion imaging in assessing chronic liver diseases: does a clinical role exist? 147
Autoimmunity and lymphoproliferation markers in naïve HCV-RNA positive patients without clinical evidences of autoimmune/lymphoproliferative disorders 147
Deregulation of microRNA expression in peripheral blood mononuclear cells from patients with HCV-related malignancies 144
Longitudinal assessment of liver stiffness in patients undergoing antiviral treatment for hepatitis C 143
Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia 142
Host genetic determinants in HCV-related mixed cryoglobulinemia 141
Association Between Persistent Lymphatic Infection By Hepatitis C Virus After Antiviral Treatment And Mixed Cryoglobulinemia 140
A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection 140
Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection 139
Clinical significance of polymorphisms in immune response genes in hepatitis C-related hepatocellular carcinoma 138
Retreatment regimen of rituximab monotherapy given at the relapse of severe HCV-related cryoglobulinemic vasculitis: Long-term follow up data of a randomized controlled multicentre study 138
Treatment of HCV-related mixed cryoglobulinemia 138
Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals? 137
AISF position paper on HCV in immunocompromised patients 137
Hepatitis B virus related cryoglobulinemic vasculitis: A multicentre open label study from the Gruppo Italiano di Studio delle Crioglobulinemie - GISC 137
Modifications of plasma platelet-activating factor (PAF)- acetylhydrolase/PAF system activity in patients with chronic hepatitis C virus infection 137
Non-invasive assessment of liver fibrosis in patients with HBV-related chronic liver disease undergoing antiviral treatment: A preliminary study 135
Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1 135
Clinical epidemiology of chronic viral hepatitis B: A Tuscany real-word large-scale cohort study 135
Direct antiviral agents for treatment-naïve patients with genotype 1 hepatitis C: A statistical model for comparing outcomes between real world and clinical trials 134
Amplification of hepatitis delta virus RNA sequences by polymerase chain reaction: a tool for viral detection and cloning 133
MicroRNA expression in hepatitis C virus-related malignancies: A brief review 132
A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3 131
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 130
Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: A prospective, controlled, open-label, cohort study. 129
B-cells and mixed cryoglobulinemia 128
Effect of antiviral treatment in patients with chronic HCV infection and t(14;18) translocation 127
International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement 127
Impact of safety-related dose reductions or discontinuations on sustained virologic response in HCV-infected patients: Results from the GUARD-C Cohort 125
"Inapparent" hepatitis B virus infection and hepatitis C virus replication in alcoholic subjects with and without liver disease 124
Host genetic determinants in HCV-related mixed cryoglobulinemia 123
IgG3 subclass: A possible trigger of mixed cryoglobulin cascade in hepatitis C virus chronic infection 122
Chronic hepatitis C and B-cell non-Hodgkin's lymphoma 120
Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease 120
Longitudinal assessment of liver stiffness in patients undergoing antiviral treatment for hepatitis C. 119
From current status to optimization of HCV treatment: Recommendations from an expert panel 119
Effect of alpha-interferon on hepatitis C virus chronic infection in mixed cryoglobulinemia patients 118
Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN) 118
Effect of chronic hepatitis C virus infection on inflammatory lipid mediators 118
Current and future challenges in HCV: insights from an Italian experts panel 117
HBV and HCV chronic infection: Autoimmune manifestations and lymphoproliferation 116
Longitudinal evaluation of liver stiffness and outcomes in patients with chronic hepatitis C before and after short- and long-term IFN-free antiviral treatment 116
Direct medical costs associated with the extrahepatic manifestations of hepatitis C infection in Europe 116
Reducing the price of new hepatitis C drugs in the Tuscany region of Italy 115
Can BAFF promoter polymorphism be a predisposing condition for HCV-related mixed cryoglobulinemia? 115
Can type C hepatitis infection be complicated by malignant lymphoma? 113
COMBINED PRESENCE OF HCVRNA SEQUENCES AND T(14;18) (q32;q21) TRANSLOCATION IN PBMC FROM PATIENTS WITH CHRONIC HCV INFECTION. 113
Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel 112
Real life experiences in HCV management in 2018 112
Interferon and thymosin combination therapy in naive patients with chronic hepatitis C. Preliminary results 111
Impaired response to alpha interferon in patients with an inapparent hepatitis B and hepatitis C virus coinfection 111
T(14;18) translocation in chronic hepatitis C virus infection 110
Hepatitis C virus core protein expression in human B-cell lines does not significantly modify main proliferative and apoptosis pathways 110
Infection of peripheral mononuclear blood cells by hepatitis C virus 110
Involvement of PI3K in HCV-related lymphoproliferative disorders 110
CD81 modulation by immobilized monoclonal antibodies is able to promote B-cell proliferation and c-myc expression 110
Association between mixed cryoglobulinemia, translocation (14;18), and persistence of occult HCV lymphoid infection after treatment 110
Hepatitis C virus persistence in human hematopoietic cells injected into scid mice. 109
AISF position paper on liver transplantation and pregnancy: Women in Hepatology Group, Italian Association for the Study of the Liver (AISF) 109
Epidemiological, demographic and clinical data on chronic viral hepatitis C in Tuscany 109
Patterns and mechanisms of hepatitis B/hepatitis D reinfection after liver transplantation 108
Transient elastography for the assessment of liver fibrosis in patients with chronic viral hepatitis: The missing tool? 108
HCV Patients Psychopathology and Tryptophan Metabolism: Analysis of the Effects of Pegylated Interferon plus Ribavirin Treatment 107
HCV-related mixed cryoglobulinemia and BAFF promoter polymorphism 107
Erectile dysfunction and hepatitis C virus infection 106
Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients. 106
Correction: Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER cohort study (PLoS ONE (2017) 12: 2 (e0172159) DOI: 10.1371/journal.pone.0172159) 106
Vertical transmission of HCV. 106
Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis 105
Hepatitis C virus (HCV) in cryoglobulinaemic leukocytoclastic vasculitis (LCV): could the presence of HCV in skin lesions be related to T CD8+ lymphocytes, HLA-DR and ICAM-1 expression? 105
HCV core protein expression in human B cell lines does not significantly modify proliferative and apoptosis pathways. 104
CD81 MODULATION BY IMMOBILIZED MONOCLONAL ANTIBODIES IS ABLE TO PROMOTE B-CELL PROLIFERATION AND C-MYC EXPRESSION 104
Hepatitis C virus syndrome: A constellation of organ- and non-organ specific autoimmune disorders, B-cell non- Hodgkin's lymphoma, and cancer 104
Totale 15.052
Salva come PNG Salva come JPEG
Categoria #
all - tutte 115.112
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 115.112
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204.405 0 0 0 0 647 766 649 768 599 380 510 86
2020/20214.885 412 228 273 704 197 640 194 436 426 778 253 344
2021/20223.285 49 397 150 154 112 129 109 212 120 98 543 1.212
2022/20237.696 875 1.073 303 535 729 1.661 964 385 770 49 239 113
2023/20242.265 142 390 574 119 143 269 35 368 36 70 61 58
2024/202511.310 711 2.158 1.388 2.815 4.238 0 0 0 0 0 0 0
Totale 41.612